L. Wright

419 total citations
7 papers, 297 citations indexed

About

L. Wright is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L. Wright has authored 7 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 2 papers in Surgery and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L. Wright's work include Colorectal Cancer Treatments and Studies (4 papers), Drug Transport and Resistance Mechanisms (2 papers) and Cancer Treatment and Pharmacology (2 papers). L. Wright is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Drug Transport and Resistance Mechanisms (2 papers) and Cancer Treatment and Pharmacology (2 papers). L. Wright collaborates with scholars based in United States, Austria and Germany. L. Wright's co-authors include Paula M. Fracasso, Sherry A. Goodner, Matthew A. Arquette, Ramaswamy Govindan, Suzanne F. Jones, Howard A. Burris, Gregory M. Springett, Christopher R. Garrett, Amit Pathak and George R. Simon and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

L. Wright

7 papers receiving 287 citations

Peers

L. Wright

ONCOL

MB

PRM

RNMI

ID

Peter Nygren Sweden

Joanna C. Masters United States

Christopher Sweeney United States

Kyung‐Hun Lee South Korea

J. H. M. Schellens Netherlands

Theresa Dunn Germany

Y. M. Rustum United States

G. A. Taylor United Kingdom

Hiroto Kishi Japan

Marta Capelán United Kingdom

Peter Nygren Sweden

L. Wright

184 ×0.9

ONCOL

141 ×1.4

MB

54 ×1.0

PRM

23 ×0.5

RNMI

13 ×0.6

ID

Citations per year, relative to L. Wright L. Wright (= 1×) peers Peter Nygren

Countries citing papers authored by L. Wright

Since Specialization

Citations

This map shows the geographic impact of L. Wright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Wright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Wright more than expected).

Fields of papers citing papers by L. Wright

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Wright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Wright. The network helps show where L. Wright may publish in the future.

Co-authorship network of co-authors of L. Wright

This figure shows the co-authorship network connecting the top 25 collaborators of L. Wright. A scholar is included among the top collaborators of L. Wright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Wright. L. Wright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Baranda, Joaquina, G. Reed, Stephen K. Williamson, et al.. (2012). A Phase I Trial of Irinotecan (IRI) and BKM120 in Previously Treated Patients (PTS) With Metastic Colorectal Cancer (MCRC). Annals of Oncology. 23. ix223–ix223. 2 indexed citations

2.

Karthaus, Meinolf, Ralf‐Dieter Hofheinz, Laurent Mineur, et al.. (2009). Epidermal growth factor receptor (EGFR) inhibitor–related skin toxicity: Review of interim data from a phase II study (20060314) of panitumumab (pmab) with FOLFIRI in the first-line treatment of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 27(15_suppl). e20634–e20634. 6 indexed citations

3.

Greil, Richard, Henry Letocha, Érick Gamelin, et al.. (2009). Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 27(15_suppl). 4085–4085. 4 indexed citations

4.

Fracasso, Paula M., Howard A. Burris, Matthew A. Arquette, et al.. (2007). A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing. Clinical Cancer Research. 13(3). 986–993. 120 indexed citations

5.

Fracasso, Paula M., Kristie A. Blum, Benjamin Tan, et al.. (2005). Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. British Journal of Cancer. 93(1). 46–53. 24 indexed citations

6.

Fracasso, Paula M., Lori J. Goldstein, Dinesh P. de Alwis, et al.. (2004). Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies. Clinical Cancer Research. 10(21). 7220–7228. 62 indexed citations

7.

Giles, Francis J., Paula M. Fracasso, Hagop M. Kantarjian, et al.. (2003). Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leukemia Research. 27(12). 1077–1083. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact